KOD · Healthcare
Kodiak Sciences Inc
24/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
32
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$2.5B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGM
About KODIAK SCIENCES INC
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical…
Who's behind the signal
Every informed buyer we can see on KOD, across all three feeds.
Hedge funds · 6
Tudor Investment (Paul Tudor Jones)
New position
Citadel Advisors
Increased +200%
AQR Capital Management
Increased +49%
Point72 (Steve Cohen)
Decreased −79%
D.E. Shaw & Co
Decreased −28%
Millennium Management (Englander)
Decreased −76%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 1 on record
Disclosures from 2022-07-18 to 2022-07-18
The newest disclosure we hold for this stock is 2022-07-18.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
| Trade date | Member | Chamber | Action | Amount |
|---|---|---|---|---|
| 2022-07-18 | Chris Jacobs · R-NY | House | Bought | $1,001 - $15,000 |
Not a model pick — but on our radar.
KODIAK SCIENCES INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
1
New positions
2
Increasing
3
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
% of portfolio
0.0%
Position change
NEW
0.0% of Tudor Investment's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+200%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+49%
0.0% of AQR Capital Management's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
−79%
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−28%
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−76%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to KODIAK SCIENCES INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell KODIAK SCIENCES INC or any security.
Get the Weekly Update
Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime